190 related articles for article (PubMed ID: 37992259)
1. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic
Batalini F; Madison RW; Sokol ES; Jin DX; Chen KT; Decker B; Pavlick DC; Frampton GM; Wulf GM; Garber JE; Oxnard G; Schrock AB; Tung NM
JCO Precis Oncol; 2023 Sep; 7():e2300091. PubMed ID: 37992259
[TBL] [Abstract][Full Text] [Related]
2. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
5. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
6. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
7.
Petracci FE; Villarreal-Garza C; Argañaraz F; Abuin GG; Peñaloza J; Flores MA; Piazzoni L; Riggi C; Fabiano L; González L; Cieplinski B; Rivero S; Korbenfeld E; Mandó P
Ecancermedicalscience; 2023; 17():1634. PubMed ID: 38414929
[TBL] [Abstract][Full Text] [Related]
8. Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis.
Cheng JM; Canzoniero J; Lee S; Soni S; Mangini N; Santa-Maria CA
Breast Cancer Res Treat; 2023 Jun; 199(2):389-397. PubMed ID: 37002487
[TBL] [Abstract][Full Text] [Related]
9. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
12. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
13. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Gruber JJ; Afghahi A; Timms K; DeWees A; Gross W; Aushev VN; Wu HT; Balcioglu M; Sethi H; Scott D; Foran J; McMillan A; Ford JM; Telli ML
Nat Cancer; 2022 Oct; 3(10):1181-1191. PubMed ID: 36253484
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
[TBL] [Abstract][Full Text] [Related]
17. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
18. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract][Full Text] [Related]
20. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia L; Perez A; Marchetti C; Brando C; Gristina V; Cancelliere D; Pivetti A; Contino S; Di Giovanni E; Barraco N; Bono M; Giurintano A; Bazan Russo TD; Gottardo A; Cutaia S; Pedone E; Peri M; Corsini LR; Fanale D; Galvano A; Scambia G; Badalamenti G; Russo A; Bazan V
Cancer Treat Rev; 2023 Dec; 121():102650. PubMed ID: 37939446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
